Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

MetaVia Inc.

NASDAQ: MTVA · Life Sciences · 8 alerts · CIK 1638287

Share price
$1.21Close, Nov 16
Market cap
$8.13M
Shares outstanding
6.74MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All MetaVia Inc. filings on SEC EDGAR ↗

9:01 AM ET 8-K
Clinical Trial Data

MetaVia Clinical Trial Data

MetaVia announced the completion of the final patient visit in its Phase 1 Part 3A study of DA-1726, a dual GLP-1/glucagon receptor agonist. The company also highlighted interim Part 3B data showing a 68.1% placebo-adjusted reduction in liver fat and 13.5% weight loss, with full data from both parts expected in Q1 2027.

9:02 AM ET 8-K
Clinical Trial Data

MetaVia Clinical Trial Data

MetaVia presented positive preclinical data at ObesityWeek® 2026 comparing its dual-receptor agonist DA-1726 against retatrutide in diet-induced obese mice. The study showed DA-1726 achieved comparable weight loss with less appetite suppression and superior glucose lowering, while significantly increasing hepatic FGF21 expression. The company plans to advance DA-1726 into a Phase 2 study for MetALD and ALD in the second half of 2027.

8:37 AM ET 10-Q
Financial Results

MetaVia Q3 2026 Results: Net Loss of $4.62M, Loss Widens

MetaVia Inc. reported a net loss of $13.8 million for the nine months ended September 30, 2026, compared to $11.0 million in the prior year, driven by increased research and development expenses. The company's cash position decreased to $8.8 million from $10.3 million at year-end 2025, while total stockholders' equity fell to $2.4 million.

Key figure
Net loss $4.62M
8:36 AM ET 8-K
Financial Results

MetaVia Financial Results

MetaVia Inc. reported third quarter 2026 financial results and provided a corporate update on its clinical pipeline, including positive Phase 1 interim data for DA-1726 in liver-related cardiometabolic diseases. The company also announced the appointment of Dr. Sarah Browne as Chief Medical Officer and plans to initiate a Phase 2 study in MetALD and ALD in the second half of 2027.

Term
Q3 2026

“The positive interim results from our Phase 1 Part 3B study of DA-1726, a novel oxyntomodulin (OXM) analog and dual GLP-1/glucagon receptor agonist, were recently highlighted in an oral presentation at the Precision Liver Symposium. We believe these findings provide important clinical support for DA-1726's potential to treat metabolic dysfunction and alcohol-associated liver disease (MetALD), as well as alcohol-associated liver disease (ALD).”

Hyung Heon Kim, President and Chief Executive Officer

“Last month, we also expanded our clinical leadership team with the appointment of Sarah Browne, M.D., as Chief Medical Officer. Sarah brings more than 20 years of experience spanning clinical development, regulatory science and clinical medicine, including leading the development of pemvidutide, a dual GLP-1/glucagon receptor agonist, through Phase 2 and establishing Phase 3 development strategies.”

Hyung Heon Kim, President and Chief Executive Officer
8:42 AM ET 8-K
Clinical Trial Data

MetaVia Clinical Trial Data

MetaVia announced additional positive data from Part 3B of its Phase 1 clinical trial of DA-1726, demonstrating a statistically significant 1.47 mg/dL placebo-adjusted reduction in serum uric acid after 16 weeks. These results complement previously reported data showing a 68.1% reduction in liver fat and 13.5% weight loss, supporting the drug's advancement into a Phase 2 study for MetALD and ALD planned for late 2027.

9:16 AM ET 8-K
Clinical Trial Data

MetaVia Clinical Trial Data

MetaVia announced positive interim data from Part 3B of its Phase 1 trial for DA-1726, showing a statistically significant 68% placebo-adjusted reduction in liver fat and 13.5% weight loss after 16 weeks. The results support the company's plan to initiate a Phase 2 study in patients with MetALD and ALD in the second half of 2027.

“These are the most compelling clinical data we have generated to date supporting DA-1726’s potential as a liver-focused cardiometabolic therapy. A 68% placebo-adjusted reduction in liver fat after approximately 16 weeks, together with all five participants who entered the study with liver steatosis achieving MRI-PDFF below 5%, provides a strong clinical rationale for expanding DA-1726 into liver disease.”

Hyung Heon Kim, President and Chief Executive Officer

“The next step for DA-1726 is clear. We intend to build on these results by advancing the program into both metabolic dysfunction and alcohol-associated liver disease (MetALD) and alcohol-associated liver disease (ALD), where there are currently no approved therapies specifically for these patient populations.”

Hyung Heon Kim, President and Chief Executive Officer
9:01 AM ET 8-K
Business Update

MetaVia Business Update

MetaVia announced that an abstract for its Phase 1 clinical trial of DA-1726, a dual GLP-1 and glucagon receptor agonist, has been accepted for an oral presentation at the Precision Liver Symposium 2026. The presentation, scheduled for November 4, 2026, will highlight data regarding weight loss and reduction in MRI-PDFF (liver fat) in patients. While the filing mentions previous trial findings, it does not disclose the specific new data points or results that will be presented at the upcoming conference.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.